said its subsidiary hVivo has signed a deal with a major pharmaceutical client to manufacture a virus for use in human challenge studies.
Manufacturing has already begun, and the work is expected to be completed by the end of the third quarter.
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:
Congrats Cathal.